Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Antibodies to modulate surface receptor systems are often bivalent and must compete in a two-dimensional cell contact region.

Schmidt BJ, Bee C, Han M, Jing Y, Cheng Y, Tenney DJ, Leil TA.

CPT Pharmacometrics Syst Pharmacol. 2019 Sep 17. doi: 10.1002/psp4.12468. [Epub ahead of print]


Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.

Balsitis S, Gali V, Mason PJ, Chaniewski S, Levine SM, Wichroski MJ, Feulner M, Song Y, Granaldi K, Loy JK, Thompson CM, Lesniak JA, Brockus C, Kishnani N, Menne S, Cockett MI, Iyer R, Mason SW, Tenney DJ.

PLoS One. 2018 Feb 14;13(2):e0190058. doi: 10.1371/journal.pone.0190058. eCollection 2018.


High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.

Wichroski MJ, Fang J, Eggers BJ, Rose RE, Mazzucco CE, Pokornowski KA, Baldick CJ, Anthony MN, Dowling CJ, Barber LE, Leet JE, Beno BR, Gerritz SW, Agler ML, Cockett MI, Tenney DJ.

PLoS One. 2012;7(8):e42609. doi: 10.1371/journal.pone.0042609. Epub 2012 Aug 6.


A novel small molecule inhibitor of hepatitis C virus entry.

Baldick CJ, Wichroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, Pokornowski KA, Rose RE, Eggers BJ, Hsu M, Zhai W, Zhai G, Gerritz SW, Poss MA, Meanwell NA, Cockett MI, Tenney DJ.

PLoS Pathog. 2010 Sep 2;6(9):e1001086. doi: 10.1371/journal.ppat.1001086.


Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.

Walsh AW, Langley DR, Colonno RJ, Tenney DJ.

PLoS One. 2010 Feb 12;5(2):e9195. doi: 10.1371/journal.pone.0009195.


Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U.

Hepatology. 2010 Feb;51(2):422-30. doi: 10.1002/hep.23327.


Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B.

Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M.

Hepatol Int. 2009 Jun;3(2):403-10. doi: 10.1007/s12072-008-9108-8. Epub 2008 Dec 9.


Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates.

Fang J, Wichroski MJ, Levine SM, Baldick CJ, Mazzucco CE, Walsh AW, Kienzle BK, Rose RE, Pokornowski KA, Colonno RJ, Tenney DJ.

Antimicrob Agents Chemother. 2009 Jul;53(7):2762-72. doi: 10.1128/AAC.00130-09. Epub 2009 May 11.


Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ.

Hepatology. 2009 May;49(5):1503-14. doi: 10.1002/hep.22841.


Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.

Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group.

Hepatology. 2008 Jul;48(1):99-108. doi: 10.1002/hep.22323.


Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance.

Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, Yu CF, Colonno RJ.

Hepatology. 2008 May;47(5):1473-82. doi: 10.1002/hep.22211.


Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.

Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, Yu CF, Tenney DJ, Colonno RJ.

J Hepatol. 2008 Jun;48(6):895-902. doi: 10.1016/j.jhep.2007.12.024. Epub 2008 Feb 21.


Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.

Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ.

Antimicrob Agents Chemother. 2008 Feb;52(2):598-605. Epub 2007 Dec 3.


Inhibition of hepatitis B virus polymerase by entecavir.

Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, Kapur AJ, Colonno RJ, Tenney DJ.

J Virol. 2007 Apr;81(8):3992-4001. Epub 2007 Jan 31.


Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.

Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ.

Antimicrob Agents Chemother. 2007 Mar;51(3):902-11. Epub 2006 Dec 18.


Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.

Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ.

Hepatology. 2006 Dec;44(6):1656-65.


Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ.

Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507.


Herpes simplex virus DNA cleavage and packaging proteins associate with the procapsid prior to its maturation.

Sheaffer AK, Newcomb WW, Gao M, Yu D, Weller SK, Brown JC, Tenney DJ.

J Virol. 2001 Jan;75(2):687-98.


Evidence for controlled incorporation of herpes simplex virus type 1 UL26 protease into capsids.

Sheaffer AK, Newcomb WW, Brown JC, Gao M, Weller SK, Tenney DJ.

J Virol. 2000 Aug;74(15):6838-48.


Isolation of herpes simplex virus procapsids from cells infected with a protease-deficient mutant virus.

Newcomb WW, Trus BL, Cheng N, Steven AC, Sheaffer AK, Tenney DJ, Weller SK, Brown JC.

J Virol. 2000 Feb;74(4):1663-73.


Physical and functional interactions between the herpes simplex virus UL15 and UL28 DNA cleavage and packaging proteins.

Koslowski KM, Shaver PR, Casey JT 2nd, Wilson T, Yamanaka G, Sheaffer AK, Tenney DJ, Pederson NE.

J Virol. 1999 Feb;73(2):1704-7.


Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.

Tenney DJ, Yamanaka G, Voss SM, Cianci CW, Tuomari AV, Sheaffer AK, Alam M, Colonno RJ.

Antimicrob Agents Chemother. 1997 Dec;41(12):2680-5.


The pseudorabies virus UL28 protein enters the nucleus after coexpression with the herpes simplex virus UL15 protein.

Koslowski KM, Shaver PR, Wang XY, Tenney DJ, Pederson NE.

J Virol. 1997 Dec;71(12):9118-23.


The human cytomegalovirus UL98 gene encodes the conserved herpesvirus alkaline nuclease.

Sheaffer AK, Weinheimer SP, Tenney DJ.

J Gen Virol. 1997 Nov;78 ( Pt 11):2953-61.


Developmental analysis of the cytomegalovirus enhancer in transgenic animals.

Baskar JF, Smith PP, Ciment GS, Hoffmann S, Tucker C, Tenney DJ, Colberg-Poley AM, Nelson JA, Ghazal P.

J Virol. 1996 May;70(5):3215-26.


The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice.

Baskar JF, Smith PP, Nilaver G, Jupp RA, Hoffmann S, Peffer NJ, Tenney DJ, Colberg-Poley AM, Ghazal P, Nelson JA.

J Virol. 1996 May;70(5):3207-14.


Characterization of monoclonal antibodies recognizing amino- and carboxy-terminal epitopes of the herpes simplex virus UL42 protein.

Sheaffer AK, Hurlburt WW, Stevens JT, Bifano M, Hamatake RK, Colonno RJ, Tenney DJ.

Virus Res. 1995 Oct;38(2-3):305-14.


Sequence-dependent primer synthesis by the herpes simplex virus helicase-primase complex.

Tenney DJ, Sheaffer AK, Hurlburt WW, Bifano M, Hamatake RK.

J Biol Chem. 1995 Apr 21;270(16):9129-36.


The herpes simplex virus type 1 DNA polymerase accessory protein, UL42, contains a functional protease-resistant domain.

Hamatake RK, Bifano M, Tenney DJ, Hurlburt WW, Cordingley MG.

J Gen Virol. 1993 Oct;74 ( Pt 10):2181-9.


The human cytomegalovirus US3 immediate-early protein lacking the putative transmembrane domain regulates gene expression.

Tenney DJ, Santomenna LD, Goudie KB, Colberg-Poley AM.

Nucleic Acids Res. 1993 Jun 25;21(12):2931-7.


Deletions of the carboxy terminus of herpes simplex virus type 1 UL42 define a conserved amino-terminal functional domain.

Tenney DJ, Hurlburt WW, Bifano M, Stevens JT, Micheletti PA, Hamatake RK, Cordingley MG.

J Virol. 1993 Apr;67(4):1959-66.


Mutations in the C terminus of herpes simplex virus type 1 DNA polymerase can affect binding and stimulation by its accessory protein UL42 without affecting basal polymerase activity.

Tenney DJ, Micheletti PA, Stevens JT, Hamatake RK, Matthews JT, Sanchez AR, Hurlburt WW, Bifano M, Cordingley MG.

J Virol. 1993 Jan;67(1):543-7.


Human cytomegalovirus US3 and UL36-38 immediate-early proteins regulate gene expression.

Colberg-Poley AM, Santomenna LD, Harlow PP, Benfield PA, Tenney DJ.

J Virol. 1992 Jan;66(1):95-105.


Expression of the human cytomegalovirus UL36-38 immediate early region during permissive infection.

Tenney DJ, Colberg-Poley AM.

Virology. 1991 May;182(1):199-210.


Differentiation of the U937 macrophage cell line removes an early block of HSV-1 infection.

Tenney DJ, Morahan PS.

Viral Immunol. 1991 Summer;4(2):91-102.


Effect of macrophage activation on resistance of mouse peritoneal macrophages to infection with herpes simplex virus types 1 and 2.

Sit MF, Tenney DJ, Rothstein JL, Morahan PS.

J Gen Virol. 1988 Aug;69 ( Pt 8):1999-2010.


Supplemental Content

Loading ...
Support Center